← United States · Coverage record
US · SEC FORM 4
Bespoke Extracts, Inc.
BSPK · — · CIK 0001409197 · Healthcare · Drug Manufacturers—Specialty & Generic
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
Insider activity timeline
No Form 4 transaction event is present in the current 180-day window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-09-11 · FEINSOD MICHAEL.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
The FINRA report lists no short interest for this ticker.
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-09-11 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 1,500 | USD 0.27 | USD 405 | SEC filing ↗ |
| 2025-09-10 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 2,000 | USD 0.19 | USD 380 | SEC filing ↗ |
| 2025-09-08 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 2,500 | USD 0.19 | USD 475 | SEC filing ↗ |
| 2025-09-05 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 2,500 | USD 0.20 | USD 500 | SEC filing ↗ |
| 2025-07-02 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 8,000 | USD 0.11 | USD 880 | SEC filing ↗ |
| 2025-05-12 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 1,000 | USD 0.10 | USD 100 | SEC filing ↗ |
| 2025-05-09 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 1,000 | USD 0.11 | USD 110 | SEC filing ↗ |
| 2025-01-31 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 2,000 | USD 0.11 | USD 220 | SEC filing ↗ |
| 2025-01-30 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 1,000 | USD 0.11 | USD 110 | SEC filing ↗ |
| 2025-01-23 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 3,500 | USD 0.10 | USD 350 | SEC filing ↗ |
| 2025-01-22 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 4,500 | USD 0.11 | USD 495 | SEC filing ↗ |
| 2025-01-03 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 4,500 | USD 0.10 | USD 450 | SEC filing ↗ |
| 2025-01-02 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 8,500 | USD 0.11 | USD 935 | SEC filing ↗ |
| 2024-11-14 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 1,500 | USD 0.19 | USD 285 | SEC filing ↗ |
| 2024-11-12 | FEINSOD MICHAEL | Purchase (P) | Common Stock | 2,500 | USD 0.16 | USD 400 | SEC filing ↗ |
Form 4 evidence
2 transaction lines in the latest 365-day window; 65 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | Garth Tyler Hunter | Award / grant (A) | Common Stock | 200,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-19 | FEINSOD MICHAEL | Award / grant (A) | Common Stock | 1,000 | USD 0.20 | USD 200 | SEC filing ↗ |
Show recent Form 4 evidence (2 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | Garth Tyler Hunter | Award / grant (A) | Common Stock | 200,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-19 | FEINSOD MICHAEL | Award / grant (A) | Common Stock | 1,000 | USD 0.20 | USD 200 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-19 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | BSPK |
| CIK | 0001409197 |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | — |
Data coverage
| Local Form 4 history | 65 transaction lines from 2020-03-25 to 2025-12-30 47 P purchase lines · 3 S sale lines · 15 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.